Faster mental decline in 866 Scots tracked with low NRF2 in the cells that build myelin

Among 866 people from the Lothian Birth Cohort 1936 who completed extra cognitive testing after age 70, those whose thinking declined fastest also tended to have lower levels of a protein called NRF2 in their oligodendrocytes, the brain cells that make myelin. The work was led from the University of Edinburgh and reported in Nature Medicine. It is an association measured in living and then deceased volunteers, paired with a mouse experiment that points toward a mechanism without proving one in people.

The tech news worth your time: 400,000+ professionals from Google, Apple and OpenAI read Techpresso, a daily email with the most interesting tech news and insights.

Subscribe to Techpresso →

We may earn a commission if you sign up.

Myelin is the fatty insulation that wraps nerve fibres and keeps signals moving quickly. Oligodendrocytes are the cells that build it.

The Lothian Birth Cohort 1936 and its testing record

The Lothian Birth Cohort 1936 enrolled 1,091 people, according to the University of Edinburgh’s account of the study. Of those, 866 completed additional cognitive testing after age 70, with assessments of memory, processing speed and spatial reasoning repeated between ages 70 and 82. Having so many tests per person is what lets researchers measure the rate of decline instead of a single snapshot of ability, and the Edinburgh team stressed that the brain changes they found tracked that rate rather than a person’s level of ability at any one time.

Brain tissue was donated after death by a subset of participants. The published summaries do not give the size of that subset.

The cohort design also sets the boundaries of the result. The Lothian Birth Cohort 1936 is, as the name says, a group of people born in a single year in the Lothian region of Scotland, which gives the researchers an unusually well-matched set of volunteers to follow but also means the findings come from one generation in one part of the world. Whether the same pattern holds in people of other ages, backgrounds or countries is a separate question that this study was not built to answer, and the authors would need independent groups of older adults to test it.

NRF2 and the cells that build myelin

In the donated tissue, people who had declined faster showed fewer large nerve fibres and an excess of myelin, a pairing that runs against the intuition that more insulation must be better. The same people had lower levels of NRF2 inside their oligodendrocytes, as the ScienceDaily summary of the paper reports. NRF2 is the protein at the centre of the story, and its shortfall in these specific cells is the molecular marker that lined up with both the tissue changes and the faster slide in testing.

Veronique Miron, an MRC senior fellow and group leader at the UK Dementia Research Institute who leads the Edinburgh group, framed the work against a rising burden of cognitive decline in an ageing population and the absence of current treatments. First author Georgina Craig, a postdoctoral fellow at St Michael’s Hospital in Toronto and the institute, said the results changed how researchers regard these cells in ageing; she noted that oligodendrocytes had long been considered purely beneficial, a view the new data complicate, as the institute’s news item describes.

Cutting NRF2 in mice

Human tissue can only show what travels together, so the team ran a test in animals. They specifically reduced NRF2 in the oligodendrocytes of mice. The animals developed excessive myelin and lost large nerve fibres, resembling what the human tissue showed, and they also showed smaller cognitive improvements as they aged. That experiment is the causal test in this work, and it supports the idea that low NRF2 in these cells can produce the structural changes seen in people. The release does not give the mouse strain, group sizes or the method used to lower the protein.

The distinction matters for how far the claim can travel. In the 866-person cohort the finding is a correlation: low NRF2 and faster decline appeared together, and the study design cannot say which came first or whether another factor drives both. The mouse result narrows the gap but is a model of one cell type under controlled conditions, and ageing human brains differ in many other ways.

Even so, the finding gives researchers a specific cell type and a specific protein to follow up. Earlier thinking treated oligodendrocytes mostly as support staff for neurons, and a result that ties their NRF2 level to the pace of mental decline suggests that the health of the insulation-makers, and not only the neurons they serve, deserves attention in studies of how the ageing brain loses speed and memory.

A multiple sclerosis drug on the same pathway

The practical lead comes from medicine already in use. Existing drugs act on the NRF2 pathway, including one prescribed for multiple sclerosis, and the Edinburgh release says that increasing NRF2 activity has improved cognitive function in people with that disease. The sources do not name the drug. Miron’s group sees that overlap as a reason to examine whether repurposing such a treatment could help slow age-related decline, a possibility the researchers raise rather than a result they have tested in older adults without multiple sclerosis.

Funding came from the UK Medical Research Council and the Canadian Institutes of Health Research. The full paper, titled Oligodendrocyte dysfunction in human age-related cognitive decline, appears in Nature Medicine, and the institute’s publication record lists the authors from Edinburgh, Toronto and Northwestern University.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

The tech news worth your time: Subscribe to Techpresso →

We may earn a commission if you sign up.